Search results for "cancer."
showing 10 items of 11362 documents
Tumor-derived exosomes as factors that promote metastatic niche formation: evaluation of the effects induced by colon cancer derived exosomes on func…
2023
Estudio de la expresión de marcadores de transición epitelio-mesenquimal y de célula madre cancerosa en el melanoma cutáneo, y su asociación con la p…
2015
La mayoría de los estudios epidemiológicos muestran un aumento en la incidencia de melanoma en las últimas décadas, sobre todo a expensas de un aumento en la incidencia de melanomas delgados. La búsqueda de nuevos marcadores pronósticos y predictivos incluye el estudio de el fenómeno de transición epitelio-mesenquimal (EMT) que consiste en un proceso dinámico por el que las células adquieren progresivamente un fenotipo mesenquimal, con pérdida de las uniones célula-célula, modificaciones en el citoesqueleto y adquisición de marcadores como cadherina-N, osteonectina/SPARC, osteopontina, fibronectina, Twist y Snail. Por otro lado, en el modelo de tumorigénesis de la célula madre cancerosa (CM…
Impressive objective response to nab-paclitaxel plus trastuzumab as fifth line therapy in aelderly her2-positive breast cancer patient
2020
Agent targeting HER-2 pathway plus chemotherapy has represented a major progress in the management of patients with breast cancer. However the role of late-line treatment in heavily pretreated patients is largely unclear. In the last decade nab-paclitaxel has show significant activity and good toxicity profile in metastatic breast cancer. We report the case of a 76-year-old Caucasian woman with metastatic HER-2 positive ductal infiltrating breast carcinoma treated with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line therapy. She had previously received first-line paclitaxel and trastuzumab, second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral ca…
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell L…
2022
Background: Despite the increasing implementation of targeted and immunotherapy-based treatments, the prognosis of patients with advanced NSCLC remains dismal. We prospectively evaluated longitudinal plasma cfDNA kinetics as an early marker of therapeutic efficacy in patients with advanced NSCLC undergoing standard first-line treatments. Methods: From February 2020 to May 2022, treatment-naïve patients with advanced NSCLC were consecutively enrolled at the Medical Oncology Unit of the Paolo Giaccone University Hospital, Palermo (Italy). We quantified cfDNA in terms of ng/μL using a QubitTM dsDNA HS Assay Kit. The agreement between the cfDNA and radiologic response was evaluated from…
Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older Women in Germany and the United States
2020
Background: Breast cancer treatment has changed tremendously over the last decades. In addition, the use of mammography screening for early detection has increased strongly. To evaluate the impact of these developments, long-term trends in incidence, mortality, stage distribution and survival were investigated for Germany and the United States (US). Methods: Using population-based cancer registry data, long-term incidence and mortality trends (1975&ndash
Survival trends for primary liver cancer, 1995–2009: analysis of individual data for 578,740 patients from 187 population-based registries in 36 coun…
2019
CONCORD Working Group Members: Africa—Algeria: S Bouzbid (Registre du Cancer d’Annaba); M Hamdi-Chérif*, Z Zaidi (Registre du Cancer de Sétif); Gambia: R Swaminathan (National Cancer Registry); Lesotho: SH Nortje (Children’s Haematology Oncology Clinics - Lesotho); Libya: MM El Mistiri (Benghazi Cancer Registry); Mali: S Bayo, B Malle (Kankou Moussa University); Mauritius: SS Manraj, R Sewpaul-Sungkur (Mauritius National Cancer Registry); Nigeria: A Fabowale, OJ Ogunbiyi* (Ibadan Cancer Registry); South Africa: D Bradshaw, NIM Somdyala (Eastern Cape Province Cancer Registry); DC Stefan (Umtata University); Tunisia: L Jaidane, M Mokni (Registre du Cancer du Centre Tunisien). America (Central…
The synergistic effect exerted by the HDAC inhibitor SAHA and the sesquiterpene lactone parthenolide on triple negative breast canc er cells
2014
Triple-negative breast cancer (TNBC) is a subtype o f breast cancer, insensitive to endocrine therapy. Chemotherapy is the main form of treatment, but is accompanied by a high rate of recidivism. The sesquiterpene lactone Parthenolide (PN) exerts a cy totoxic effect on MDA-MB231 cells, a TNBC cell line (1), but was ineffective at low doses (2-5μM). This repr esents an obstacle for a therapeutic utilization of PN. We supposed, in line with other authors (2), that PN c auses a protective response, which at low doses pre vails on the cytotoxic effect. With the aim of inhibiting this protective effect we have shown that pre-trea tment of MDA-MB231 cells with SAHA (2-5μM), an histone deace tylat…
Trombocitozes saistība ar ne-sīkšūnu plaušu vēža pacientu demogrāfiskajiem un klīniskajiem faktoriem
2019
Ievads. Lai gan tiek izstrādātas arvien efektīvākas ļaundabīgo audzēju agrīnas skrīninga un diagnostikas metodes, ne-sīkšūnu plaušu vēzis vēl joprojām pārsvarā tiek atklāts III vai IV stadijā, līdz ar to tas ir viens no vadošajiem audzējiem mirstības ziņā. Trombocīti piedalās vēža šūnu augšanā un tālākā izplatīšanā pa organismu. Ne-sīkšūnu plaušu vēža pacientiem bieži ir palielināts trombocītu skaits, kas ir saistīts ar sliktu prognozi. Tamdēļ, ir būtiski noskaidrot vai pastāv kādi ne-sīkšūnu plauša vēža pacienta demogrāfiskie vai klīniskie rādītāji, kam ir korelācija ar trombocitozi. Tas ļautu laicīgi paredzēt to, ka pacientam iespējams būs palielināts trombocītu skaits un izrietoši sliktā…
Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments
2021
Muscle wasting, i.e., cachexia, frequently occurs in cancer and associates with poor prognosis and increased morbidity and mortality. Anticancer treatments have also been shown to contribute to sustainment or exacerbation of cachexia, thus affecting quality of life and overall survival in cancer patients. Pre-clinical studies have shown that blocking activin receptor type 2 (ACVR2) or its ligands and their downstream signaling can preserve muscle mass in rodents bearing experimental cancers, as well as in chemotherapy-treated animals. In tumor-bearing mice, the prevention of skeletal and respiratory muscle wasting was also associated with improved survival. However, the definitive proof tha…
Extracellular Vesicles as Shuttles of Tumor Biomarkers and Anti-Tumor Drugs
2014
Extracellular vesicles (EV) include vesicles released by either normal or tumor cells. EV may exceed the nanometric scale (microvesicles), or to be within the nanoscale, also called exosomes. Thus, it appears that only exosomes and larger vesicles may have the size for potential applications in nanomedicine, in either disease diagnosis or therapy. This is of particular interest for research in cancer, also because the vast majority of existing data on EV are coming from pre-clinical and clinical oncology. We know that the microenvironmental features of cancer may favor cell-to-cell paracrine communication through EV, but EV have been purified, characterized, and quantified from plasma of tu…